This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
by Zacks Equity Research
BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
Apyx Medical's (APYX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Apyx Medical (APYX).
Here's Why Momentum Investors Will Love Apyx Medical (APYX)
by Zacks Equity Research
Does Apyx Medical (APYX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Hill-Rom (HRC) to Boost Cardiology Portfolio with New Buyout
by Zacks Equity Research
Hill-Rom's (HRC) acquisition of Bardy Diagnostics enables the former to expand into ambulatory cardiac monitoring space to accelerate digital health offering.
Apyx (APYX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apyx (APYX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx (APYX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 18.75% and 3.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Apyx Medical (APYX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 17.65% and 71.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Apyx Medical (APYX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Surges: Stock Moves 10.3% Higher
by Zacks Equity Research
NanoString Technologies (NSTG) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Agios Gets Orphan Drug Tag for Mitapivat to Treat Thalassemia
by Zacks Equity Research
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.
Why Apyx (APYX) Stock Might be a Great Pick
by Zacks Equity Research
Apyx (APYX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Canopy Growth (CGC) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Canopy Growth (CGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Will Apyx Medical Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Apyx Medical
Quidel (QDEL) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Quidel (QDEL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
PetIQ (PETQ) Catches Eye: Stock Jumps 8.4%
by Zacks Equity Research
PetIQ (PETQ) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Apyx Medical (APYX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 72.73% and -5.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Apyx (APYX) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Top Ranked Momentum Stocks to Buy for November 21st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 21st
Will Apyx Medical Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Apyx Medical.
Apyx (APYX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 27.78% and 13.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Apyx Medical (APYX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.